{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:29:27Z","timestamp":1773710967587,"version":"3.50.1"},"reference-count":69,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2016,5,3]]},"DOI":"10.1586\/17512433.2016.1156529","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T06:16:18Z","timestamp":1455948978000},"page":"637-645","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":53,"title":["Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus"],"prefix":"10.1586","volume":"9","author":[{"given":"Adam","family":"Strzelczyk","sequence":"first","affiliation":[{"name":",","place":["Germany"]},{"name":",","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl Martin","family":"Klein","sequence":"additional","affiliation":[{"name":",","place":["Germany"]},{"name":",","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent M.","family":"Willems","sequence":"additional","affiliation":[{"name":",","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[{"name":",","place":["Germany"]},{"name":",","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[{"name":",","place":["Germany"]},{"name":",","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,3,7]]},"reference":[{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826060-00002"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002033420503"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004418"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.02.006"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70193-4"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02973.x"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13089"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2010.09.037"},{"key":"e_1_3_2_13_1","first-page":"27","article-title":"Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany","author":"Strzelczyk A","year":"2013","unstructured":"Strzelczyk A, Haag A, Reese JP, et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav. 2013;27:433\u2013438.","journal-title":"Epilepsy Behav"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21064"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02929.x"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.198"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.04.064"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.10.048"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201200183"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.3.361"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12347"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.221"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.004"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.12360"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm030913e"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12973"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2007.11.021"},{"key":"e_1_3_2_29_1","volume-title":"Summary of opinion (initial authorisation) for Briviact (brivaracetam) [EMA\/CHMP\/742520\/2015]","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. Summary of opinion (initial authorisation) for Briviact (brivaracetam) [EMA\/CHMP\/742520\/2015]. London: UK European Medicines Agency; 2015."},{"key":"e_1_3_2_30_1","volume-title":"Briviact - Annex I - Summary of product characteristics","author":"European Medicines Agency","year":"2016","unstructured":"European Medicines Agency. Briviact - Annex I - Summary of product characteristics. London, UK: European Medicines Agency; 2016."},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.09.005"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03158.x"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.017129"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02829.x"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011431457"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.82"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.09.001"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S81474"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-14-RG-010"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2015.03.003"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.446"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12535"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000271385.85302.55"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ec7f7f"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03598.x"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12433"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13212"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12391"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12432"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2015.04.017"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1058360"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802278453"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03208.x"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.0420s4024.x"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02782.x"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.09.024"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13223"},{"issue":"8","key":"e_1_3_2_58_1","first-page":"53","article-title":"UCB 34714, a new pyrrolidone derivative, suppresses seizures epileptogenesis in animal models of chronic epilepsy in vivo","volume":"44","author":"Matagne A","year":"2003","unstructured":"Matagne A, Kenda B, Michel P, et al. UCB 34714, a new pyrrolidone derivative, suppresses seizures epileptogenesis in animal models of chronic epilepsy in vivo. Epilepsia. 2003;44(Suppl. 8):53\u20133, A072.","journal-title":"Epilepsia"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000297512.18364.40"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-007-0788-3"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13275"},{"key":"e_1_3_2_62_1","first-page":"361","article-title":"The unified myoclonus rating scale","volume":"89","author":"Frucht SJ","year":"2002","unstructured":"Frucht SJ, Leurgans SE, Hallett M, et al. The unified myoclonus rating scale. Adv Neurol. 2002;89:361\u2013376.","journal-title":"Adv Neurol"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2014.11.003"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2013.08.003"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws091"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr215"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02366.x"},{"issue":"8","key":"e_1_3_2_68_1","first-page":"219","article-title":"Brivaracetam is a potent anticonvulsant in experimental status epilepticus","volume":"46","author":"Wasterlain C","year":"2005","unstructured":"Wasterlain C, Suchomelova L, Matagne A, et al. Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia. 2005;46(Suppl. 8):219.","journal-title":"Epilepsia"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13267"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03243.x"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2015.1091303"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu339"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285615589711"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/17512433.2016.1156529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:57:27Z","timestamp":1770379047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/17512433.2016.1156529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,7]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5,3]]}},"alternative-id":["10.1586\/17512433.2016.1156529"],"URL":"https:\/\/doi.org\/10.1586\/17512433.2016.1156529","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}